Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-0.56% $1.790
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 95.14 mill |
EPS: | -1.390 |
P/E: | -1.290 |
Earnings Date: | May 09, 2024 |
SharesOutstanding: | 53.15 mill |
Avg Daily Volume: | 0.364 mill |
RATING 2024-03-28 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Strong Buy | |
P/E: | Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | |||
Gr.Profit | n/a | |||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -1.290 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.22x |
Company: PE -1.290 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$-0.897 (-150.10%) $-2.69 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 1.603 - 1.977 ( +/- 10.45%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-06-07 | Wills Robert James | Buy | 30 000 | Stock Option (right to buy) |
2023-06-07 | Tomsicek Michael John | Buy | 30 000 | Stock Option (right to buy) |
2023-06-07 | Pasternak Richard C | Buy | 30 000 | Stock Option (right to buy) |
2023-06-07 | Liebert Debra K. | Buy | 30 000 | Stock Option (right to buy) |
2023-06-07 | Giles Lisa M. | Buy | 30 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
3.02 |
Last 95 transactions |
Buy: 18 033 611 | Sell: 4 881 578 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $1.790 (-0.56% ) |
Volume | 0.454 mill |
Avg. Vol. | 0.364 mill |
% of Avg. Vol | 124.91 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.